| Patient | Florence Griffith Joyner |
|---|---|
| Date of birth | 1989-12-21 |
| Identifiers | MRN HR-ML033-SYN; SSN (made up) 000-33-2648 |
| Document date | 2026-05-27 |
| Author | Celeste Vanterpool, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three weeks on levetiracetam; neurosurgical opinion; SUDEP and safety counseling. [S]
Ms. Griffith Joyner returns three weeks after starting levetiracetam. She has taken every dose. In the first ten days she felt short-tempered and more tired than usual after training; both are easing. She has had no seizure or spell. The neurosurgeon saw her last week and offered complete removal of the cavernous malformation with its hemosiderin rim through a left frontal craniotomy; she has chosen surgery, booked in three weeks. She wears the detection watch at night. She has not driven. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Levetiracetam | Every dose taken; irritability and tiredness easing |
| Seizures | None since the flight |
| Neurosurgery | Lesionectomy offered and chosen; booked in three weeks |
| Safety | Detection watch at night; not driving |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | More tired than usual after training, improving |
| Neurological | Negative | No seizures, spells, headache or dizziness |
| Psychiatric | Positive | Short-tempered in the first ten days, easing; sleep normal; PHQ-9 6; no thoughts of self-harm |
| Musculoskeletal | Negative | Training without injury |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | One tablet twice daily | Oral route | 2026-05-05 | active | S |
| Folic acid 0.4 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-05 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-27 | Body height | 170 | cm | S |
| 2026-05-27 | Body weight | 60.8 | kg | S |
| 2026-05-27 | Body mass index (BMI) [Ratio] | 21 | kg/m2 | S |
| 2026-05-27 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-05-27 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-05-27 | Heart rate | 60 | /min | S |
| 2026-05-27 | Respiratory rate | 14 | /min | S |
| 2026-05-27 | Body temperature | 36.7 | Cel | S |
| 2026-05-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 2026-05-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 60.8 kg; blood pressure 114/72, pulse 60 |
| Neurological | Alert; speech, strength, coordination and gait normal |
| Psychiatric | Calm and engaged; describes the irritability with insight |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Generalized tonic-clonic seizure on a flight two and a half weeks ago, in a 36-year-old woman who was observed overnight in hospital elsewhere and has had treatment for seizures in the past, records requested; no antiseizure medication now; normal examination today. Evaluated as a new seizure: EEG and MRI of the brain with susceptibility-weighted imaging ordered, neurology (epilepsy) review booked, and no driving | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to her publicly reported seizure on a flight; superseded by the diagnosis at the epilepsy consultation. |
| Focal epilepsy with structural cause: focal to bilateral tonic-clonic seizure from a left orbitofrontal cavernous malformation, with left frontal epileptiform discharges on EEG; epilepsy under the ILAE 2014 practical definition (an unprovoked seizure with a recurrence risk above 60% from an epileptogenic lesion, and earlier seizures by history); synthetic modern detail linked to her publicly reported seizures and the coroner's finding | active | confirmed | G40.209 | S — Synthetic seizure type, EEG and classification; the seizures and the cavernous angioma of the left orbital frontal cerebrum are documented (D). |
| Solitary cerebral cavernous malformation, 1.4 cm, left orbitofrontal cortex, with a hemosiderin rim and an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging (sporadic pattern); no acute hemorrhage | active | confirmed | Q28.3 | S — Synthetic imaging detail; the coroner reported a congenital cavernous angioma of the left orbital frontal cerebrum (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 6, from 3: irritability and tiredness on levetiracetam, easing; no thoughts of self-harm |
| Self-management | Seizure diary and adherence | Each visit | Completed today | No seizure; every dose taken |
| Referral | Neurosurgical evaluation of an epileptogenic cavernous malformation | When a cavernous malformation causes epilepsy | Up to date | Seen last week; lesionectomy chosen and booked |
| Self-management | SUDEP counseling | At diagnosis of epilepsy | Completed today | Discussed today, three weeks after the diagnosis (deviation recorded at the last visit): what SUDEP is, that tonic-clonic seizures are the main risk factor, and that the best protection is no tonic-clonic seizures, with every dose taken, regular sleep and little alcohol; nocturnal supervision or detection. No harm from the delay: no seizure in the interval. Corrective action: SUDEP added to the clinic's checklist for every new diagnosis of epilepsy |
| Self-management | Nocturnal seizure detection | When seizures may occur in sleep | Completed today | Wrist-worn detection watch worn every night, alerting a contact she chose |
| Self-management | Driving restriction and the California physician report | From the first seizure until cleared | Up to date | Not driving |
| Self-management | Seizure safety: water, heights, sleep and first aid | At diagnosis and each visit | Completed today | Reviewed; she follows the plan |
| Medication safety | Folic acid and contraception | Each visit | Completed today | Folic acid taken daily; no pregnancy planned |
Goal progress:
Guideline basis: Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015); Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014); Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017); Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017); Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024); Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021); Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Lesionectomy in three weeks. Primary care review about five weeks after surgery. Call at once for another seizure, worsening mood, or any thoughts of self-harm. Next scheduled visit 2026-07-21: five weeks after lesionectomy: recovery, seizure control, return to training. [S]